This is a must-have resource for biotech entrepreneurs and investors, as well as invaluable supplementary reading for students aspiring to a career in the industry. In particular, it illustrates the tensions between both sides based on their different backgrounds and expectations. The book outlines the various funding opportunities for the biotech industry in Europe and identifies ways for both...

This is a must-have resource for biotech entrepreneurs and investors, as well as invaluable supplementary reading for students aspiring to a career in the industry. In particular, it illustrates the tensions between both sides based on their different backgrounds and expectations. The book outlines the various funding opportunities for the biotech industry in Europe and identifies ways for both...

This paper shows that active investors, such as venture capitalists, can affect the speed at which new ventures grow. In the absence of product market competition, new ventures financed by active investors grow faster initially, though in the long run those financed by passive investors are able to catch up. By contrast, in a competitive product market, new ventures financed by active investors...

This is a must-have resource for biotech entrepreneurs and investors, as well as invaluable supplementary reading for students aspiring to a career in the industry. In particular, it illustrates the tensions between both sides based on their different backgrounds and expectations. The book outlines the various funding opportunities for the biotech industry in Europe and identifies ways for both...

With robust growth and comparatively stable economy, India continues to be a key and fast developing market across the world. Number of foreign companies operating in India grows 100% every year. Yet India is still to embark upon a law that matches to developed nations’ legal system and meets investors’ expectations. However, the courts in India have used existing laws to afford protection and ...

The variance risk premium, defined as the difference between the actual and riskneutral expectations of the forward aggregate market variation, helps predict future market returns. Relying on new essentially model-free estimation procedure, we show that much of this predictability may be attributed to time variation in the part of the variance risk premium associated with the special compensati...

This paper presents a simple rational expectations model of intertemporal asset pricing relating instability of stock return characteristics to heterogeneity in investor preferences. Heterogeneity is likely to generate declining aggregate relative risk aversion. This leads to variability in expected asset returns, volatility, and autocorrelation. The stronger this variability is, the more heter...

This is a must-have resource for biotech entrepreneurs and investors, as well as invaluable supplementary reading for students aspiring to a career in the industry. In particular, it illustrates the tensions between both sides based on their different backgrounds and expectations. The book outlines the various funding opportunities for the biotech industry in Europe and identifies ways for both...

In this study, we focus on the impact of senior executives' industry backgrounds on the amount of capital raised in the stock market. The primary contribution of the study entails applying the upper echelon theory to the initial public offering (IPO) phenomenon. Specifically, we hypothesize that the industry backgrounds of corporate executives affect the amount of capital that the firm raised i...

We study a standard consumption based asset pricing model with rational investors who entertain subjective prior beliefs about price behavior. Optimal behavior then dictates that investors learn about price behavior from past price observations. We show that this imparts momentum and mean reversion into the equilibrium behavior of the price dividend ratio, similar to what can be observed in the...